Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.

Feng-Cai ZhuShang-Ying HuYing HongYue-Mei HuXun ZhangYi-Ju ZhangQin-Jing PanWen-Hua ZhangFang-Hui ZhaoCheng-Fu ZhangXiaoping YangJia-Xi YuJiahong ZhuYejiang ZhuFeng ChenQian ZhangHong WangChangrong WangJun BiShiyin XueLingling ShenYan-Shu ZhangYunkun HeHaiwen TangNaveen KarkadaPemmaraju SuryakiranDan BiFrank Struyf

Published in: Cancer medicine (2019)

NCT00779766.

Keyphrases

phase ii
clinical trial
open label
study protocol
polycystic ovary syndrome
cervical cancer screening
high grade
type diabetes
double blind
skeletal muscle
adipose tissue